Overall, 60 patients received ≥1 dose of 6.4 mg/kg T-DXd (colorectal cancer, n = 20; NSCLC, n = 18; and other, n = 22, including 8 salivary gland tumors; 2 breast cancers (1 HER2 low and 1 HER2 status missing per central laboratory assessment); 2 esophageal cancers; 2 endometrial cancers; 2 Paget disease; 2 biliary tract cancer; and 1 case each of pancreatic cancer, uterine cervix carcinoma, extraskeletal myxoid chondrosarcoma, and small-intestine adenocarcinoma). This evidence concerns the gene ERBB2 and extraskeletal myxoid chondrosarcoma.